HCY swabs are widely used in research projects, have appeared many times in Nature
Huachenyang (Shenzhen) Tech Co., Ltd. was founded in 2008, and in the 14 years since its establishment, the company has owned 79 patents. It has been focusing on biological consumables and reagents, taking a leading position in the field.
Huachenayng has established good relationships with more than 30 universities, 50 national research institutions, and 200 tertiary hospitals in China. More than 10 experiments/projects published in Nature, Cell, and EClinicalMedicine have chosen Huachenyang’s swabs.
Some of the projects that used Huachenyang’s swabs
![Nature Communication](https://www.chenyanglobal.com/wp-content/uploads/2022/08/1.1_8.1.jpg)
1.
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Publications: Nature Medicine
Date of publication: 2021
![Nature Communication](https://www.chenyanglobal.com/wp-content/uploads/2022/08/2.1_2.1.jpg)
2.
Microbiota the microbiota continuum along the female reproductive tract and its relation to uterine-related disease
Publications: Nature Communication
Date of publication: 2017
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/3.1_1.1.jpg)
3.
Discrepant gut microbiota markers for the classifcation of obesity related metabolic abnormalities
Publications: Nature Scientific Reports
Date of publication: 2019
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/4.1_6.1.jpg)
4.
Detection of persistent SARS‑CoV‑2 IgG antibodies in oral mucosal fuid and upper respiratory tract specimens following COVID‑19 mRNA vaccination
Publications: Nature Scientific Reports
Date of publication: 2021
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/5.1_4.1.jpg)
5.
Analytic comparison between three high‑throughput commercial SARS‑CoV‑2 antibody assays reveals minor discrepancies in a high‑incidence population
Publications: Nature Scientific Reports
Date of publication: 2021
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/6.1_10.1.jpg)
6.
Therapeutic efficacy of macrolides in management of patients with mild COVID‑19
Publications: Nature Scientific Reports
Date of publication: 2021
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/7.1_5.1.jpg)
7.
Characterizing the Qatar advanced‑phase SARS‑CoV‑2 epidemic
Publications: Nature Scientific Reports
Date of publication: 2021
![Nature Scientific Reports](https://www.chenyanglobal.com/wp-content/uploads/2022/08/8.1_7.1.jpg)
8.
Gene‑environment interactions between CREB1 and childhood maltreatment on aggression among male Chinese adolescents
Publications: Nature Scientific Reports
Date of publication: 2022
![Cell iScience](https://www.chenyanglobal.com/wp-content/uploads/2022/08/9.1_3.1.jpg)
9.
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
Publications: Nature Cell iScience
Date of publication: 2021
![Emerging Microbes & Infections](https://www.chenyanglobal.com/wp-content/uploads/2022/08/10.1_11.1.jpg)
10.
Human papillomavirus prevalence and associated
factors in women and men in south China: a
population-based study
Publications: Emerging Microbes & Infections
Date of publication: 2016
![Eclinical Medicine](https://www.chenyanglobal.com/wp-content/uploads/2022/08/11.1_13.1.jpg)
11.
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Publications: eClinical Medicine
Date of publication: 2021
![medRxiv](https://www.chenyanglobal.com/wp-content/uploads/2022/08/12.1_9.1.jpg)
12.
SARS-CoV-2 reinfection in a cohort of 43,000 antibody positive individuals followed for up to 35 weeks
Publications: medRxiv
Date of publication: 2021
More and more scientific research, medical and governmental institutions choose Huachenyang’s products, which is not only the recognition and trust of our products but also gives us an additional responsibility. Huachenyang will continue to increase its independent research and development investment, actively introduce high-end biotechnology talents and technology, continue to deepen its work in the field of biological consumables and reagents and continue to provide the market with high-quality and stable products.
Huchenyang‘ Flocked Swabs
![Flocked Swabs](https://en.huachenyang.com/wp-content/uploads/2020/06/详情页3-e1657016559275.jpg)